NMS · Biotechnology

IMVT (IMVT) Stock

$39.63 -2.91% NMS: IMVT Healthcare

Valuation

MetricValue
Price$39.63
Market Cap$8.18B
P/E Ratio-14.48
P/B Ratio11.41
P/S Ratio1187.50
EPS (TTM)$-2.67
52-Week High$45.42
52-Week Low$14.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.59%
ROA-63.13%
ROCE-76.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio15.74

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-156.0M$-208.0M$-270.0M$-438.0M$-533.0M
Net Profit$-157.0M$-211.0M$-259.0M$-414.0M$-506.0M
EPS$-1.43$-1.71$-1.88$-2.73$-2.77
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$516.0M$406.0M$667.0M$776.0M$958.0M
Total Liabilities$46.0M$43.0M$49.0M$69.0M$105.0M
Cash$494.0M$377.0M$635.0M$714.0M$902.0M
Borrowings$2.0M$1.0M$0$0$0

Latest News

Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? Zacks · Jun 19, 2026 Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight PR Newswire · Jun 18, 2026 Immunovant Stock Gains 12.4% in a Month: What's Driving It? Zacks · Jun 12, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-106.0M$-188.0M$-214.0M$-376.0M$-407.0M
Investing Cash Flow$-1.0M$0$-1.0M$-2.0M$0
Financing Cash Flow$200.0M$0$0$4.0M$-1.0M
Net Cash Flow$94.0M$-117.0M$259.0M$79.0M$188.0M
Free Cash Flow$-106.0M$-188.0M$-215.0M$-377.0M$-407.0M

Ownership

Insiders Held56.56%
Institutions Held54.64%
Institutions Float Held125.76%
Institutional HolderSharesReport Date
FMR, LLC16,947,8882026-03-31
Deep Track Capital, Lp11,526,9712026-03-31
Blackrock Inc.6,574,4972026-03-31
Baker Bros. Advisors, LP5,457,8812026-03-31
State Street Corporation4,537,9292026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $28.84 -0.24% 8.94 $4.94B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
CRNX $84.95 +0.00% -16.80 $9.00B 0.00%
DYN $25.14 -1.16% -7.64 $4.69B 0.00%
KYMR $117.38 -1.20% -36.35 $9.66B 0.00%

About IMVT

IMVT is led by CEO Eric Venker, employs 315 people, headquartered in Durham, US, publicly traded since 2019.

IMVT stock trades at $39.63 with a market capitalization of $8.18B. The stock is valued at a price-to-earnings (P/E) ratio of -14.48, price-to-book of 11.41, price-to-sales of 1187.50. Over the past 52 weeks the stock has ranged between $14.58 and $45.42, and currently trades 12.7% below its 52-week high.

On profitability, IMVT generates a return on equity (ROE) of -69.59%, return on capital employed of -76.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.27 +0.22% JNJ Drug Manufacturers - General $271.38 +2.08% ABBV Drug Manufacturers - General $259.96 +1.38% MRK Drug Manufacturers - General $149.64 +1.27% UNH Medical - Healthcare Plans $396.26 +1.76% NVS Drug Manufacturers - General $161.16 +5.98% AZN Drug Manufacturers - General $162.19 +0.04% AMGN Drug Manufacturers - General $438.17 +1.93% TMO Medical - Diagnostics & Research $599.60 -2.84% NVO Biotechnology $45.08 -0.55% ABT Medical - Devices $108.74 -1.47% GILD Drug Manufacturers - General $149.44 +2.12%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides